Company Overview - Ekso Bionics focuses on developing exoskeleton solutions to enhance human strength, endurance, and mobility[6] - The company has deployed over 900 devices in more than 450 centers worldwide[7, 12, 37] Financial Performance & Market Opportunity - In 2023, Ekso Bionics generated $15.4 million in clinical revenue[6] - The company is targeting positive operating cash flow through revenue growth and improved efficiencies[7, 71] - The total potential addressable market for personal mobility exoskeletons in the USA is estimated at ~$34 billion, including potential future neurodegenerative indications and general debility usage[55] Reimbursement & Market Access - CMS reimbursement for Ekso Indego Personal is established at $91,000, effective April 1, 2024[7, 50] - CMS & VA covered individuals with SCI is ~176,000[52] - The company is leveraging clinical relationships and partnerships for efficient market access[56, 57] Product Portfolio - The company offers a range of products, including EksoNR and Ekso Indego Therapy for neuro-rehabilitation[6] - Ekso is developing the Nomad device, with a limited research release in 2024 and commercial release expected in 2025[24] - EVO is an upper body exoskeleton for industrial applications, with a potential market opportunity > $8 billion annually[60, 66]

Company Overview - Ekso Bionics is a developer of exoskeleton solutions designed to augment human strength, endurance, and mobility[6] - The company has deployed over 900 devices in more than 450 centers worldwide[7, 12, 37] Financial Performance & Market Opportunity - Ekso Bionics generated $15.4 million in clinical revenue in 2023, out of $18.2 million total revenue[6] - The company received CMS reimbursement for Ekso Indego Personal at $91,000[7, 50] - The total potential addressable market for personal mobility exoskeletons is estimated at $13.1 billion, including potential future neurodegenerative indications in the USA[55] - The long-term potential market for general debility usage is estimated at $34 billion, based on 1.5 million manual wheelchair users in the USA[55] - The company's revenue for FY 2023 was $18.3 million, a 42% increase compared to $13.0 million in FY 2022[71, 75] Market Reach & Strategy - The company leverages a clinical installed base of approximately 260 US centers to reach patients with spinal cord injuries[7] - Ekso Bionics is focused on achieving positive operating cash flow through scaling revenue growth and improving operating efficiencies[7, 82] - The company is expanding its market reach across the care continuum, from outpatient to home, with the Indego product line[76] - The potential market opportunity for the EVO industrial exoskeleton in targeted segments is greater than $8 billion annually[66]